Castle Biosciences
Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping people first — the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors.
Our innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes. Please visit us at https://castlebiosciences.com/tests to learn more about our portfolio of innovative prognostic and diagnostic tests.
TissueCypher Patient Story: Why It's Good to Know Your Risk
Skip’s Melanoma Story & the Power of Personalized Testing
MyPath Test Clarifies Atypical Spitzoid Lesion in Young Adult | Dr. Etan Marks Case Review
MyPath Test Prevents Overdiagnosis of Melanoma | Dr. Etan Marks Case Study
TissueCypher Patient Story: Low Risk Brings Peace of Mind
Atypical Skin Lesion in 54-Year-Old: How MyPath Melanoma Guided Surgical Decision | Dr. Brent Moody
Subtle Facial Lesion or Early Melanoma? How Molecular Testing Changed the Plan | Dr. Brent Moody
TissueCypher patient story: The benefit of an early warning
From Diagnosis to Determination: Don's Skin Cancer Journey of Hope, Clarity and a Plan
Melanoma Changed My Life at 26 | Leah's Story of Survival, Family, and Hope
AI Unlocks the Clinical Utility of Spatialomics — Matthew Goldberg PMWC 2025
This is Castle Biosciences. Empowering people, informing care decisions.
DecisionDx-Melanoma 200K Celebration
DecisionDx-Melanoma Overview
Getting answers for the many questions of melanoma with DecisionDx-Melanoma
Streamlining Diagnosis: Dr. Neil Fernandes on the MyPath Melanoma Ordering Process
When to Use MyPath Melanoma: Dr. Neil Fernandes on Managing Ambiguous Skin Lesions
How MyPath Melanoma Resolves Uncertainty in Diagnosing Skin Lesions